Is Combined Lipid-regulating Therapy Safe and Feasible for the Very Old Patients with Mixed Dyslipidemia?

Overview

Journal J Geriatr Cardiol

Specialty Geriatrics

Date 2014 Jan 24

PMID 24454328

Citations 1

Authors

Xiao Zou

Quan-Jin Si

Affiliations

Soon will be listed here.

Abstract

Objectives: To detect the efficacy and safety of combined lipid-regulating therapies in the very old patients with mixed dyslipidemia and determine an appropriate therapy for them.

Methods: Four hundred and fifty patients aged over 75 with mixed dyslipidemia were divided into five groups according to different combination therapies. Lipid levels and drug related adverse events were tested during the study.

Results: Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were reduced in every group compared to baseline: statin + ezetimibe: -30.0% and -55.5%; statin + policosanol: -31.1% and -51.2%; statin + fibrates: -23.7% and -44.6%; statin + niacin: -25.2% and -43.0%; and niacin + fibrates: -11.3% and -23.5%. The target achievement rates of LDL-C all exceeded 50%, except in niacin + fibrates (42.0%); statin + ezetimibe: 57.0%; statin + policosanol: 56.0%; statin + niacin: 52.0%; and statin + fibrates: 50.0%. However, overall, the niacin + fibrates group was the most effective in decreasing triglyceride (TG) and increasing high-density lipoprotein cholesterol (HDL-C) as follows: niacin + fibrates: -39.3% and 28.6%; statin + fibrates: -29.3% and 18.4%; statin + niacin: -18.5% and 16.7%; statin + ezetimibe: -17.1% and 7.1%; and statin + policosanol: -15.6% and 9.5%. The achievement rates of TG and HDL-C levels in niacin + fibrates (58.0% and 39.0%) were better than the other four groups: statin + niacin (34.0% and 34.0%), statin + fibrates (43.0% and 28.0%), statin + policosanol (30.0% and 24.0%) and statin + ezetimibe (28.0% and 25.0%). Patients in all five groups experiencing drug adverse events were only 2% and no severe adverse events occurred.

Conclusions: Statin + ezetimibe was the most effective group in lowering TC and LDL-C levels, while niacin + fibrates was the most effective in decreasing TG and increasing HDL-C levels. The commonly used combined lipid-regulating therapies with common dosages in this study were all quite safe and feasible for the very old patients with mixed hyperlipidemia.

Citing Articles

Statin Therapy in Very Old Patients: Lights and Shadows.

Cobos-Palacios L, Sanz-Canovas J, Munoz-Ubeda M, Lopez-Carmona M, Perez-Belmonte L, Lopez-Sampalo A Front Cardiovasc Med. 2021; 8:779044.

PMID: 34912868 PMC: 8667269. DOI: 10.3389/fcvm.2021.779044.

References

Daskalopoulou S, Mikhailidis D . Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin. 2006; 22(3):511-28. DOI: 10.1185/030079906X89856. View

Kashani A, Sallam T, Bheemreddy S, Mann D, Wang Y, Foody J . Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008; 101(11):1606-13. DOI: 10.1016/j.amjcard.2008.01.041. View

Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A . The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol. 2007; 63(2):113-21. DOI: 10.1007/s00228-006-0238-4. View

Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D . Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2011; 59(1):50-6. DOI: 10.1016/j.jjcc.2011.09.001. View

. [Chinese guidelines on prevention and treatment of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007; 35(5):390-419. View

Berthold H, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I . Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006; 295(19):2262-9. DOI: 10.1001/jama.295.19.2262. View

McKenney J . Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. Postgrad Med. 2012; 124(1):7-20. DOI: 10.3810/pgm.2012.01.2513. View

Bays H, Ose L, Fraser N, Tribble D, Quinto K, Reyes R . A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with.... Clin Ther. 2005; 26(11):1758-73. DOI: 10.1016/j.clinthera.2004.11.016. View

Cubeddu L, Cubeddu R, Heimowitz T, Restrepo B, Lamas G, Weinberg G . Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J. 2006; 152(5):982.e1-5. DOI: 10.1016/j.ahj.2006.08.009. View

10.

Davidson M, Maccubbin D, Stepanavage M, Strony J, Musliner T . Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol. 2006; 97(2):223-8. DOI: 10.1016/j.amjcard.2005.08.038. View

11.

Natarajan P, Ray K, Cannon C . High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol. 2010; 55(13):1283-99. DOI: 10.1016/j.jacc.2010.01.008. View

12.

Lee Y, Kim M, Choi C, Bae J, Jang C, Lee S . Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults. Arch Pharm Res. 2011; 34(8):1331-7. DOI: 10.1007/s12272-011-0813-9. View

13.

Stein E . Managing dyslipidemia in the high-risk patient. Am J Cardiol. 2002; 89(5A):50C-57C. DOI: 10.1016/s0002-9149(02)02229-4. View

14.

Kashani A, Phillips C, Foody J, Wang Y, Mangalmurti S, Ko D . Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006; 114(25):2788-97. DOI: 10.1161/CIRCULATIONAHA.106.624890. View

15.

Mohiuddin S, Thakker K, Setze C, Kelly M . Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Curr Med Res Opin. 2011; 27(5):1067-78. DOI: 10.1185/03007995.2011.569018. View

16.

Sprecher D . Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am J Cardiol. 2001; 86(12A):46L-50L. DOI: 10.1016/s0002-9149(00)01470-3. View

17.

Hausenloy D, Yellon D . Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Curr Opin Cardiol. 2009; 24(5):473-82. DOI: 10.1097/HCO.0b013e32832ebfe7. View

18.

Reiner Z . Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2009; 24(1):19-28. DOI: 10.1111/j.1472-8206.2009.00764.x. View

19.

Taylor A . Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials. Am J Cardiol. 2008; 101(8A):36B-43B. DOI: 10.1016/j.amjcard.2008.02.030. View

20.

Silva M, Matthews M, Jarvis C, Nolan N, Belliveau P, Malloy M . Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007; 29(2):253-60. DOI: 10.1016/j.clinthera.2007.02.008. View